Angion Biomedica Corp. (ANGN)


0.00 (0.00%)
Symbol ANGN
Price $1
Beta 0.598
Volume Avg. 0.01M
Market Cap 30.114M
Shares () -
52 Week Range 1.0-20.4
1y Target Est -
DCF Unlevered ANGN DCF ->
DCF Levered ANGN LDCF ->
ROE -82.57% Strong Sell
ROA -95.59% Strong Sell
Operating Margin -
Debt / Equity 0.75% Neutral
P/E -0.10 Neutral
P/B 0.76 Buy


Consensus EPS

Upgrades & Downgrades

Latest ANGN news

Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D.
NASDAQ Global Select

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.